ClinicalTrials.gg
TerminatedNCT07054723GOCEUpdated Oct 28, 2026

Surviving Daily Life

An observational study in Stress, Cognitive Change and Breast Cancer, sponsored by Thomas Jefferson University. Terminated at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Thomas Jefferson University · Observational

How we know

Why this study was terminated
Insufficient Staff
Updated Oct 28, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
17
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Breast Neoplasms by Thomas Jefferson University — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Thomas Jefferson University.

Started
2025
the only one that year
Observational
5 of 20
2 open now
Registered
18th of 20
by date

Among the 20 studies in Breast Neoplasms by Thomas Jefferson University, this one is the only one that started in 2025, is one of 5 observational ones, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 20 studies in Breast Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by Thomas Jefferson University, or all of them as a file.
02

Study summary

The primary goal of this project is to evaluate the feasibility of a 14-day mobile daily diary study among racially diverse breast cancer survivors. Further, the investigators will examine the validity and reliability of the daily stress and daily cognitive performance measures among breast cancer survivors. This pilot project will recruit 30 racially diverse breast cancer survivors (Asian, Black, Latina, and white; ages 40 and older; at least five years post-diagnosis) who are patients at the Sidney Kimmel Comprehensive Cancer Center. The daily diary survey questions will be available in English, Spanish, and Chinese to accommodate the preferred language of the target participants.

Read the detailed description

This is a pilot study that will assess the feasibility of a 14-day mobile daily diary survey to measure daily stress and cognitive performance among long-term breast cancer survivors.

Participants will be recruited from the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University (TJU). Potential participants will be identified via the SKCC/TJU Tumor Registry. Potential participants will be contacted with their cancer care team approval. Contact may be accomplished via an upcoming clinical appointment, phone, email, or MyChart (RLS) depending on the patient's communication preference or clinical team guidance.

Participants will start study procedures by completing the baseline survey using the mobile phone (day 1) to collect demographic and socioeconomic status information. Starting from day 2 to day 14, participants will complete the short morning (2-3 min) and slightly longer (5-7 min) evening mobile daily diary surveys. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. The evening survey asks questions about the respondent's daily experiences (stressors, mood, physical symptoms). After each survey, respondents will complete three brief objective cognitive tasks. To minimize the risk of data breach, all the information from the survey will be stored on the password protected study mobile phone. The study mobile phones will be set up to ensure that it can only be used for study purposes, that is, participants are unable to make phone calls or connect to the internet with the study phone.

Findings from this pilot project will provide critical preliminary evidence regarding the feasibility of a mobile daily diary method among racially diverse breast cancer survivors, as well as the reliability and validity of the important measures related to daily stress, daily cognitive performance, and daily cognitive problems in racially diverse populations.

03

Conditions studied

  • Stress
  • Cognitive Change
  • Breast Cancer
  • Breast Carcinoma
  • Breast Neoplasm
  • Cognitive Dysfunction

Keywords

  • Mobile Survey
  • Daily Diary
  • Breast Cancer Survivors
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Breast cancer survivor who self-identifies as White, Black/African American, Latina, or Asian

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:

  • Individuals 40 or older
  • Five or more years after breast cancer diagnosis
  • Self-identified as Asian, Black, Latina, or white
  • Able to read in English, Spanish, or Chinese

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Under 40
  • Cannot provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
17 participants (actual)
Patient registry
No

Groups and cohorts

  • Mobile Daily Diary Survey

    Participants in the study will be given a mobile phone to complete the study. Participants will first complete the baseline survey using the mobile phone (day 1) to collect demographic and socioeconomic status information. Starting from day 2 to day 14, participants will complete the short morning (2-3 min) and slightly longer (5-7 min) evening mobile daily diary surveys. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. The evening survey asks questions about the respondent's daily experiences (stressors, mood, physical symptoms). After each survey, respondents will complete three brief objective cognitive tasks. To minimize the risk of data breach, all the information from the survey will be stored on a password protected mobile phone which will be set up to ensure that participants are only able to use the phone for the study processes, not for phone calls or to connect to the internet.

    Behavioral: Mobile Daily Diary

Interventions

  • BehavioralMobile Daily Diary

    This study will include a 14-day daily diary survey in which participants will be expected to complete morning (\~5 minutes) and night (\~10 minutes) assessments using mobile phones provided by the research team.

06

What researchers measure

Primary outcomes

  1. Completion rate of the 14-day mobile daily diary survey

    The feasibility of the mobile daily diary method will be based on calculating the percentage of completed daily diary surveys as well as percentages of completed morning and evening surveys. An accepted completion rate is predetermined at the level of 70% or higher

    Time frame: Daily, from Day 2 through Day 15

Secondary outcomes

  1. predictive validity of the Daily Inventory of Stressful Experiences (DISE)

    Predictive validity of the daily stressor exposure and severity will be conducted by testing the within-person and between-person associations between daily stressor exposure and severity with daily negative and positive affect, daily cognitive performance, and daily cognitive problems.

    Time frame: Daily, from Day 2 through Day 15

  2. predictive validity of Ambulatory Cognitive Assessment measures

    Construct validity of the daily cognitive assessment measures will be assessed by conducting a multilevel confirmatory factor analysis (CFA) to assess the fit of our hypothesized measurement model.

    Time frame: Twice Daily, from Day 2 through Day 15

  3. internal reliability of Ambulatory Cognitive Assessment measures

    Between-person reliability (higher intraclass correlation is expected, thus no calculation of within-person reliability) by calculating internal consistency (i.e., Cronbach's alpha) across all persons and days.

    Time frame: Twice Daily, from Day 2 through Day 15

  4. internal reliability of Cognitive Interference and Memory Lapses scale

    Between-person reliability (higher intraclass correlation is expected, thus no calculation of within-person reliability) by calculating internal consistency (i.e., Cronbach's alpha) across all persons and days. PROMIS® v2.0 - Cognitive Function Scoring: * Raw Score Range: Varies by short form: * 4-item: 4-20 * 6-item: 6-30 * 8-item: 8-40 T-Score Range: \~22 to 65 * Mean: 50 * Standard Deviation: 10 Interpretation: * Higher scores indicate better cognitive function (i.e., less cognitive interference). * A T-score of 60 means one SD above average (better functioning); a T-score of 40 means one SD below average (more interference) Montreal Cognitive Assessment (MoCA) Scoring: * Total Score Range: 0-30 * Cutoff for Normal Cognition: ≥26 Interpretation: * Higher scores indicate better memory and cognitive function. * Scores between 22-25 suggest mild cognitive impairment (MCI). * Scores below 22 may indicate more significant memory or cognitive issues

    Time frame: Daily, from Day 2 through Day 15

07

Study locations

1 site
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Jun 2026, 8 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Oct 2026 → Jun 2026 and completion Oct 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Oct 2, 2025
Primary completionActual
Jun 10, 2026was Oct 2026
CompletionActual
Jun 10, 2026was Oct 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Insufficient Staff
changed Oct 28, 2026
Primary completion
Oct 31, 2026→Jun 10, 2026 (actual)
Oct 28, 2026
Study completion
Oct 31, 2026→Jun 10, 2026 (actual)
Oct 28, 2026
Enrollment
30 (estimated)→17 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Terminated
    Why stopped Insufficient Staff
    Primary completion Oct 31, 2026→Jun 10, 2026 (now actual)
    Study completion Oct 31, 2026→Jun 10, 2026 (now actual)
    Enrollment 30 (estimated)→17 (actual)
    + 5 other changes: verification date, oversight details, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07054723
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Oct 2, 2025
Primary completion
Jun 10, 2026
Completion
Jun 10, 2026
Last update
Oct 28, 2026

Study contacts

Ana Maria Lopez, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion